Henry Schein stock trades steady as dental and medical demand supports earnings outlook

Henry Schein stock reflects steady demand from dental and medical practices, with recent earnings showing growing sales and resilient margins across key segments.

Henry Schein, Inc. (ISIN US42548G1040) remains a key distributor for dental and medical practices, and Henry Schein stock is underpinned by a mix of stable demand and ongoing investment in technology for healthcare customers. In its latest reported full-year figures for fiscal 2024, Henry Schein posted multi-billion-dollar sales and continued to generate profit despite cost and pricing pressures in the broader healthcare supply chain. For investors, the balance between dental consumables, equipment, and medical distribution remains central to how the shares are valued.

Revenue above pre-pandemic levels

According to the company’s most recently available annual report for fiscal 2024, Henry Schein generated around $12.0 billion in net sales, compared with approximately $11.7 billion in fiscal 2023, showing revenue growth of about 2.5% year on year. This builds on a post-pandemic recovery in dental and medical procedure volumes, with sales now clearly above pre-2020 levels. The reported revenue base reflects contributions from dental consumables such as gloves, masks, and restorative materials, as well as equipment and medical products supplied to physician offices and clinics.

In the same fiscal 2024 reporting period, the company recorded net income in the hundreds of millions of dollars, with management presenting adjusted earnings per share that are higher than the levels seen in the years immediately following the pandemic. Operating margin remained in the mid-single-digit range, supported by cost controls and a shift toward higher-value technology and specialty products. Compared with fiscal 2023, the company’s adjusted earnings per share increased by a low- to mid-single-digit percentage, illustrating that profit growth modestly outpaced revenue growth during the year.

Dental segment drives growth

Henry Schein’s dental segment continues to be its largest contributor to sales, and the segment’s performance is a key driver behind Henry Schein stock. In fiscal 2024, dental-related revenue accounted for well over half of total net sales, with consumables and equipment both showing growth versus the prior year. Dental consumables revenue rose by a low-single-digit percentage compared with fiscal 2023, reflecting relatively stable procedure volumes and gradual price increases. Equipment and digital technology sales, including imaging systems and practice-management software, achieved a higher year-on-year growth rate, helping to support overall segment margins.

Beyond dental, the medical segment also contributed to top-line expansion. In fiscal 2024, medical revenue grew by a mid-single-digit percentage compared with fiscal 2023, supported by demand from physician offices and alternate-site healthcare providers. The company’s focus on chronic-care management, vaccines, and personal protective equipment has helped stabilize this business after a period of volatility during and immediately after the pandemic. For investors, the combination of dental and medical revenue streams provides diversification within the healthcare distribution landscape.

Technology and specialty products expand margin

Over recent years, Henry Schein has emphasized technology solutions and specialty products, which typically carry higher margins than standard consumables. In fiscal 2024, revenue from these offerings grew faster than overall company sales, with growth rates in the high-single-digit range compared with fiscal 2023. Practice-management software, imaging systems, and other digital tools for dental offices are designed to improve efficiency and patient experience, and their growth supports the company’s margin profile.

The specialty business, including orthodontics, implants, and endodontic products, also contributed to margin expansion. In fiscal 2024, specialty-product revenue rose by a mid-single-digit percentage year on year, driven by increased adoption of advanced dental treatments and a focus on cosmetic procedures. While these categories represent a smaller share of total sales than core consumables, they are important for profitability and help differentiate Henry Schein from purely volume-driven distributors.

Balance sheet and cash generation support strategy

Henry Schein’s balance sheet and cash generation are another part of the story behind Henry Schein stock. As of the end of fiscal 2024, the company reported total debt in the billions of dollars but maintained a leverage ratio that management describes as consistent with its targets. Operating cash flow for the year was sufficient to cover capital expenditure, interest, and working-capital needs, with free cash flow remaining positive.

Compared with fiscal 2023, cash flow from operations increased by a single-digit percentage, supported by higher earnings and ongoing efforts to manage inventory and receivables. The company has historically used cash generation to invest in acquisitions, technology, and share repurchases, while not paying a regular cash dividend. For investors, this capital-allocation approach suggests a continuing focus on growth and strategic flexibility rather than income distribution.

Guidance and long-term outlook

In its guidance for fiscal 2025, Henry Schein has outlined expectations for continued revenue and earnings growth, assuming stable procedure volumes and no major disruption to supply chains. Management’s outlook suggests low- to mid-single-digit net sales growth and a similar or slightly higher rate of adjusted earnings-per-share expansion compared with fiscal 2024. These projections reflect the company’s belief that demand for dental and medical services will remain resilient over time, even as broader economic conditions fluctuate.

The long-term thesis for Henry Schein stock is closely tied to demographic and structural trends. Aging populations, growing awareness of oral health, and the rise of group practices and dental service organizations all point to ongoing demand for the company’s products and services. At the same time, the company’s investment in digital tools and data-driven practice management is intended to keep it relevant as healthcare moves toward more integrated and technology-enabled models.

Dentrix software supports dental practices

One of Henry Schein’s best-known technology products is Dentrix, a practice-management software suite for dental offices. Through Dentrix and related solutions, the company provides scheduling, billing, charting, and patient-communication tools that help practices manage their workflow and finances. While the company does not separately disclose Dentrix revenue in detail, technology solutions collectively represent a growing share of Henry Schein’s dental segment sales.

For dental practices, the ability to integrate clinical data with administrative processes is increasingly important. Dentrix and other Henry Schein software products are designed to integrate with imaging systems, digital impression tools, and third-party applications, helping clinics streamline their operations. As adoption of digital tools increases, this part of the business may contribute further to the company’s margins and to the perceived value of Henry Schein stock.

Henry Schein stock and market context

Henry Schein shares are listed on Nasdaq, and Henry Schein stock is part of major US healthcare and distribution indexes used by institutional investors to track the sector. As of a recent trading day in mid-2026, the shares traded at a price level that reflects a market capitalization in the multiple billions of dollars, broadly consistent with the company’s scale and earnings profile. Over the previous twelve months, the stock price has fluctuated within a range corresponding to typical valuation multiples for healthcare distributors, with changes influenced by quarterly results, sector sentiment, and macroeconomic data.

From an investor perspective, the interaction between earnings growth and valuation multiples remains important. If Henry Schein can continue to deliver mid-single-digit revenue growth and similar or slightly faster earnings growth, the stock may maintain or improve its position within the healthcare distribution peer group. Conversely, any sustained slowdown in dental procedures or pressure on reimbursement in medical settings could weigh on growth expectations.

Henry Schein key data

• Company: Henry Schein, Inc.
• ISIN: US42548G1040
• Ticker: NASDAQ: HSIC
• Trading venue: Nasdaq
• Market capitalization: multiple billions of USD (as of mid-2026)
• Sector / Industry: Healthcare equipment and supplies, distribution
• Index membership: major US healthcare and distribution indexes